DrugDashboards

Velcade

bortezomib · BORTEZOMIB 3.5 mg/1 · Injection, Powder, Lyophilized, For Solution · Intravenous; Subcutaneous · Takeda Pharmaceuticals America, Inc.

NDC 63020-0049-01 · 1 VIAL in 1 CARTON / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL · NDA · View full market →

The short version

22 companies supply this market — deep enough that no single failure threatens the supply. The price has held steady around $1508.21 per unit over the past year.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$2.04per billing unit (0.1 MG)HCPCS J9041 · Jul 1, 2026
  • Part D plans paid (avg)$1,515.66per dosage unitgross, before rebates — matched by drug name · 2024
  • Federal ceiling (Big4)$1,212.02per unitTakeda Pharmaceuticals America, Inc. · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$1000.00$2000.00Nov 2014Jul 2016$1508.21
5 price points · per · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$1,603.00
Reported to Texas DSHS · 2026 annual filing · Takeda Pharmaceuticals America, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 0.1 MG
$2.037
HCPCS J9041 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$896,761
3,243 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Is this a "specialty" drug?

There's no legal definition — it meets 2 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $3,828.13 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA021602
TE code
AP
Approval date
May 13, 2003
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of bortezomib (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
BluePoint LaboratoriesBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 3, 2026
Eugia US LLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 3, 2026
Apotex CorpBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Avenacy, LLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
BluePoint LaboratoriesBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Dr.Reddy's Laboratories, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Fresenius Kabi USA, LLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Gland Pharma LimitedBORTEZOMIB 1 mg/1Jul 15, 2026Sep 2, 2026
Gland Pharma LimitedBORTEZOMIB 2.5 mg/1Jul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BORTEZOMIB 1 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Hospira, Inc.BORTEZOMIB 2.5 mg/1Jul 15, 2026Sep 2, 2026
Meitheal Pharmaceuticals Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Ningbo Shuangcheng Pharmaceutical Co., Ltd.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
NorthStar RxLLCBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Novadoz Pharmaceuticals LLCBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Pharmascience Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Sintetica US LLCBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Somerset Therapeutics LLCBORTEZOMIB 3.5 mg/3.5mLJul 15, 2026Sep 2, 2026
Takeda Pharmaceuticals America, Inc.BORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Waverley Pharma IncBORTEZOMIB 3.5 mg/1Jul 15, 2026Sep 2, 2026
Zydus Lifesciences LimitedBORTEZOMIB 1 mg/mLJul 15, 2026Sep 2, 2026
Zydus Pharmaceuticals USA Inc.BORTEZOMIB 1 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Velcade — NDC 63020-0049-01," retrieved September 3, 2026, https://drugdashboards.com/drug/63020004901.

Free to cite with attribution — see how the data is put together.